Protease inhibitors are cost effective anti-HIV therapy

Philip Keiser, M. Kvanli, D. Turner, J. W. Smith, N. N. Nassar, C. R. Gregg

Research output: Contribution to journalArticle

Abstract

Background: Protease inhibitor (PI) therapy is associated with fewer hospitalizations and in-patient cost savings. However, these savings may be offset by increased out-patient utilization. The Dallas VA Medical Center follows - 300 active HIV patients. PI therapy was begun early in 19%. We correlated the cost of PI therapy with the monthly in-patient and out-patient HIV related costs at our hospital to determine the cost effectiveness of PI therapy. Methods: The mean monthly number of hospital days, I.D. clinic visits , E.R. visits, in-patient costs, out-patient costs, and PI were determined for the following intervals: 2/96-6/96, 7/96-11/96 & 12/96-4/97. The monthly PI cost was then correlated to the monthly in-patient and out-patient cost. Results: Hospital utilization, and HIV related costs are summarized below. 2/96-6/96 7/96-11/96 12/96-4/97 P Hospital days 167 100 62 0.013 Clinic Visits 146 138 123 0.01 E.H. Visits 11.0 2.8 2.6 0.04 In-patient costs $160.415 $96,633 $59.875 0013 Out-patient costs $44,481 $35,084 $28,337 <0.01 PI costs $3,428 $7,906 $10,199 <0.01 There was a negative correlation between PI costs and in-patient cost (r = -0.74, p< 0.01), out-patient costs (r = -0.71, p<0.01) total HIV care cost (r = -0.87, p<001) Conclusions: PI therapy is associated with decreased hospital days, I.D. clinic visits and E.R. visits. There was a significant inverse correlation between rising PI costs and decreasing in-patient and out-patient HIV related costs, suggesting that PIs are cost effective therapv for HIV.

Original languageEnglish (US)
Pages (from-to)396
Number of pages1
JournalClinical Infectious Diseases
Volume25
Issue number2
StatePublished - 1997
Externally publishedYes

Fingerprint

Protease Inhibitors
HIV
Costs and Cost Analysis
Outpatients
Therapeutics
Ambulatory Care
Cost Savings
Cost-Benefit Analysis

ASJC Scopus subject areas

  • Immunology

Cite this

Keiser, P., Kvanli, M., Turner, D., Smith, J. W., Nassar, N. N., & Gregg, C. R. (1997). Protease inhibitors are cost effective anti-HIV therapy. Clinical Infectious Diseases, 25(2), 396.

Protease inhibitors are cost effective anti-HIV therapy. / Keiser, Philip; Kvanli, M.; Turner, D.; Smith, J. W.; Nassar, N. N.; Gregg, C. R.

In: Clinical Infectious Diseases, Vol. 25, No. 2, 1997, p. 396.

Research output: Contribution to journalArticle

Keiser, P, Kvanli, M, Turner, D, Smith, JW, Nassar, NN & Gregg, CR 1997, 'Protease inhibitors are cost effective anti-HIV therapy', Clinical Infectious Diseases, vol. 25, no. 2, pp. 396.
Keiser P, Kvanli M, Turner D, Smith JW, Nassar NN, Gregg CR. Protease inhibitors are cost effective anti-HIV therapy. Clinical Infectious Diseases. 1997;25(2):396.
Keiser, Philip ; Kvanli, M. ; Turner, D. ; Smith, J. W. ; Nassar, N. N. ; Gregg, C. R. / Protease inhibitors are cost effective anti-HIV therapy. In: Clinical Infectious Diseases. 1997 ; Vol. 25, No. 2. pp. 396.
@article{a687caad5bfd427c83c5298047fc4506,
title = "Protease inhibitors are cost effective anti-HIV therapy",
abstract = "Background: Protease inhibitor (PI) therapy is associated with fewer hospitalizations and in-patient cost savings. However, these savings may be offset by increased out-patient utilization. The Dallas VA Medical Center follows - 300 active HIV patients. PI therapy was begun early in 19{\%}. We correlated the cost of PI therapy with the monthly in-patient and out-patient HIV related costs at our hospital to determine the cost effectiveness of PI therapy. Methods: The mean monthly number of hospital days, I.D. clinic visits , E.R. visits, in-patient costs, out-patient costs, and PI were determined for the following intervals: 2/96-6/96, 7/96-11/96 & 12/96-4/97. The monthly PI cost was then correlated to the monthly in-patient and out-patient cost. Results: Hospital utilization, and HIV related costs are summarized below. 2/96-6/96 7/96-11/96 12/96-4/97 P Hospital days 167 100 62 0.013 Clinic Visits 146 138 123 0.01 E.H. Visits 11.0 2.8 2.6 0.04 In-patient costs $160.415 $96,633 $59.875 0013 Out-patient costs $44,481 $35,084 $28,337 <0.01 PI costs $3,428 $7,906 $10,199 <0.01 There was a negative correlation between PI costs and in-patient cost (r = -0.74, p< 0.01), out-patient costs (r = -0.71, p<0.01) total HIV care cost (r = -0.87, p<001) Conclusions: PI therapy is associated with decreased hospital days, I.D. clinic visits and E.R. visits. There was a significant inverse correlation between rising PI costs and decreasing in-patient and out-patient HIV related costs, suggesting that PIs are cost effective therapv for HIV.",
author = "Philip Keiser and M. Kvanli and D. Turner and Smith, {J. W.} and Nassar, {N. N.} and Gregg, {C. R.}",
year = "1997",
language = "English (US)",
volume = "25",
pages = "396",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Protease inhibitors are cost effective anti-HIV therapy

AU - Keiser, Philip

AU - Kvanli, M.

AU - Turner, D.

AU - Smith, J. W.

AU - Nassar, N. N.

AU - Gregg, C. R.

PY - 1997

Y1 - 1997

N2 - Background: Protease inhibitor (PI) therapy is associated with fewer hospitalizations and in-patient cost savings. However, these savings may be offset by increased out-patient utilization. The Dallas VA Medical Center follows - 300 active HIV patients. PI therapy was begun early in 19%. We correlated the cost of PI therapy with the monthly in-patient and out-patient HIV related costs at our hospital to determine the cost effectiveness of PI therapy. Methods: The mean monthly number of hospital days, I.D. clinic visits , E.R. visits, in-patient costs, out-patient costs, and PI were determined for the following intervals: 2/96-6/96, 7/96-11/96 & 12/96-4/97. The monthly PI cost was then correlated to the monthly in-patient and out-patient cost. Results: Hospital utilization, and HIV related costs are summarized below. 2/96-6/96 7/96-11/96 12/96-4/97 P Hospital days 167 100 62 0.013 Clinic Visits 146 138 123 0.01 E.H. Visits 11.0 2.8 2.6 0.04 In-patient costs $160.415 $96,633 $59.875 0013 Out-patient costs $44,481 $35,084 $28,337 <0.01 PI costs $3,428 $7,906 $10,199 <0.01 There was a negative correlation between PI costs and in-patient cost (r = -0.74, p< 0.01), out-patient costs (r = -0.71, p<0.01) total HIV care cost (r = -0.87, p<001) Conclusions: PI therapy is associated with decreased hospital days, I.D. clinic visits and E.R. visits. There was a significant inverse correlation between rising PI costs and decreasing in-patient and out-patient HIV related costs, suggesting that PIs are cost effective therapv for HIV.

AB - Background: Protease inhibitor (PI) therapy is associated with fewer hospitalizations and in-patient cost savings. However, these savings may be offset by increased out-patient utilization. The Dallas VA Medical Center follows - 300 active HIV patients. PI therapy was begun early in 19%. We correlated the cost of PI therapy with the monthly in-patient and out-patient HIV related costs at our hospital to determine the cost effectiveness of PI therapy. Methods: The mean monthly number of hospital days, I.D. clinic visits , E.R. visits, in-patient costs, out-patient costs, and PI were determined for the following intervals: 2/96-6/96, 7/96-11/96 & 12/96-4/97. The monthly PI cost was then correlated to the monthly in-patient and out-patient cost. Results: Hospital utilization, and HIV related costs are summarized below. 2/96-6/96 7/96-11/96 12/96-4/97 P Hospital days 167 100 62 0.013 Clinic Visits 146 138 123 0.01 E.H. Visits 11.0 2.8 2.6 0.04 In-patient costs $160.415 $96,633 $59.875 0013 Out-patient costs $44,481 $35,084 $28,337 <0.01 PI costs $3,428 $7,906 $10,199 <0.01 There was a negative correlation between PI costs and in-patient cost (r = -0.74, p< 0.01), out-patient costs (r = -0.71, p<0.01) total HIV care cost (r = -0.87, p<001) Conclusions: PI therapy is associated with decreased hospital days, I.D. clinic visits and E.R. visits. There was a significant inverse correlation between rising PI costs and decreasing in-patient and out-patient HIV related costs, suggesting that PIs are cost effective therapv for HIV.

UR - http://www.scopus.com/inward/record.url?scp=33748142034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748142034&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748142034

VL - 25

SP - 396

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 2

ER -